



LATE PROGRAMME CHANGES

(Highlighted in red for quick reference)

Friday, 7 October 2016 -16:00/17:30 – page 43

Room Oslo

EDUCATIONAL SESSION

Emerging concepts in daily management of urothelial tumours

Chair: Aristotelis Bamias, Athens, Greece

Co-Chair: Vincent Khoo, London, UK

16:00 How to select systemic therapy in bladder cancer

Aristotelis Bamias, Athens, Greece

16:30 How to interpret genomic reports in the management of urothelial malignancies

Joaquim Bellmunt, Boston, MA, USA

17:00 Targeted therapies in urothelial malignancies

Jonathan Rosenberg, New York, NY, USA

Friday, 7 October 2016 - 16:00/17:30 – page 44

Room Vienna

JOINT SYMPOSIUM: ESMO-ASCO

Rare cancers

Chairs: Fortunato Ciardiello, Naples, Italy and Daniel Hayes, Ann Arbor, MI, USA

16:00 Introduction

Fortunato Ciardiello, Naples, Italy

16:05 Rare Cancers Europe

Paolo G. Casali, Milan, Italy

16:25 The “paediatric” model for rare cancer research organisation

Gilles Vassal, Villejuif, France

16:45 Clinical trials of rare cancers in the North American Cooperative Groups: The SWOG experience

Anne Schott, Ann Arbor, MI, USA

17:05 The Rare Cancer Genetics Registry in North America

Nora Horick, Boston, MA, USA

17:25 Conclusions and clinical perspectives

Daniel Hayes, Ann Arbor, MI, USA

Friday 7 October - 16:00/17:30 – page 45

Room Berlin

JOINT SYMPOSIUM: ESMO GLOBAL POLICY COMMITTEE-AORTIC-SLACOM-UICC-WHO

Innovative strategies for affordability of value based cancer care

Chairs: Alexandru Eniu, Cluj Napoca, Romania and Ahmed Elzawawy, Port Said, Egypt

16:00 Introduction

Ahmed Elzawawy, Port Said, Egypt

16:05 Core healthcare infrastructure and skills

Richard Sullivan, London, UK

16:20 WHO Essential Medicines List for cancer

Lorenzo Moja, Geneva, Switzerland

16:35 WHO Priority Medical Devices for cancer

Adriana Velazquez Berumen, Geneva, Switzerland

16:50 The realpolitik of reimbursement and pricing: What can be done

Jack Scannell, London, UK

17:05 Workforce requirements

Eduardo Cazap, Buenos Aires, Argentina

17:20 Conclusions / Questions and Answers

Alexandru Eniu, Cluj-Napoca, Romania

Saturday, 8 October 2016 - 09:15/10:30 – page 51 – revised session

Room Madrid

PROFFERED PAPER SESSION

Genitourinary tumours, non-prostate

Chair: Joaquim Bellmunt, Boston, MA, USA

Co-Chair: Bernard Escudier, Villejuif, France

09:15 **LBA31_PR** - Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study

Matthew Galsky, New York, NY, USA

09:30 **LBA32_PR** - Pembrolizumab as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study

Arjun Balar, New York, NY, USA

09:45 Immunotherapy will be “THE OPTION” in first and second line urothelial tumours

Laurence Albiges, Villejuif, France

10:00 Chemotherapy will always remain “THE BACKBONE” in urothelial tumours

Viktor Grünwald, Hannover, Germany

10:30 Discussion

Saturday, 8 October 2016 - 11:00/12:30 – page 57

Room Madrid

PROFFERED PAPER SESSION

Basic science and translational research

Chair: Joan Seoane, Barcelona, Spain

Co-Chair: Richard Marais, Manchester, UK

11:00 **15190** - Availability of tumour gene expression data facilitates clinical decision-making for patients with advanced cancers

Janessa Laskin, Vancouver, BC, Canada

11:15 **520** - Assessment and comparison of tumor mutational burden and microsatellite instability status in >40,000 cancer genomes

David Fabrizio, Cambridge, MA, USA

11:30 Invited discussant abstracts 15190 and 520

Sheila Singh, Toronto, ON, Canada

11:45 **10** - EPHA2 blockade overcomes primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC)

Giulia Martini, Naples, Italy

12:00 **15200** - Lurbinectedin (PM01183) exhibits antitumor activity in PARP-inhibitor resistant germline BRCA PDX and lacks cross-resistance with cisplatin

Cristina Cruz, Barcelona, Spain

12:15 Invited discussant abstracts 10 and 15200

Joan Seoane, Barcelona, Spain

Saturday, 8 October 2016 - 13:00/13:45 – page 61

Room Vienna

KEYNOTE LECTURE

Response and resistance to PD-1 blockade therapy

Chair: Rolf A. Stahel, Zurich, Switzerland

13:00 **Antoni Ribas, Los Angeles, CA, USA**

Melanoma and other skin tumours

Chair: Olivier Michielin, Lausanne, Switzerland

Co-Chair: Paul Lorigan, Manchester, UK

14:45 **LBA39** - (Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma - initial data from the OpACIN trial

Christian Blank, Amsterdam, Netherlands

14:57 **LBA40** - Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study of first-line dabrafenib + trametinib vs vemurafenib in patients with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma

Caroline Robert, Villejuif, France

15:09 **11110** - Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone

Antoni Ribas, San Francisco, CA, USA

15:21 Invited discussant abstracts LBA39, LBA40 and 11110

Celeste Lebbé, Paris, France

15:36 **11060** - Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)

Paolo Ascierto, Naples, Italy

15:48 **11070** - Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma

Omid Hamid, Los Angeles, CA, USA

16:00 Invited discussant abstracts 11060 and 11070

Olivier Michielin, Lausanne, Switzerland

Saturday, 8 October 2016 - 14:45/16:15 – page 64

Room Brussels

JOINT SYMPOSIUM: ESMO-SIOPE

From childhood to adulthood: Cancer in adolescents and young adults

Chairs: Jean-Yves Douillard, Lugano, Switzerland and Stefan Bielack, Stuttgart, Germany

14:45 Introduction

Jean-Yves Douillard, Lugano, Switzerland

14:50 Adolescents and young adults with cancer: A no man's land?

Giannis Mountzios, Athens, Greece

15:10 Colorectal cancer in young adults: The focus on hereditary cancer syndromes

Emmanouil Saloustros, Heraklion, Greece

15:30 GU tumours in adolescent and young adults: Focus on germ-cell tumours

Gabriele Calaminus, Bonn, Germany

15:50 Subsequent malignant neoplasms in survivors from childhood cancers

Raoul Reulen, Birmingham, UK

16:10 Conclusions and clinical perspectives

Stefan Bielack, Stuttgart, Germany

Saturday, 8 October 2016 - 16:30/ 17:30 – page 69

Room Rome

CONTROVERSY SESSION

Should every metastatic prostate cancer patient get germline testing?

Chair: Rob Bristow, Toronto, ON, Canada

16:30 Introduction and first vote

Rob Bristow, Toronto, ON, Canada

16:40 Yes

Elena Castro, Madrid, Spain

17:00 No

Bertrand Tombal, Brussels, Belgium

17:20 Second vote and conclusions

Rob Bristow, Toronto, ON, Canada

CNS tumours

Co-Chairs: Andreas Hottinger, Lausanne, Switzerland and Deborah Blumenthal, Tel Aviv, Israel

326PD - Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM)

Martin van den Bent, Rotterdam, Netherlands

327PD - PD-L1 and IL17 expression in tumor infiltrating lymphocytes are opposite prognostic factors in glioblastoma

Bruno Chauffert, Amiens, France

328PD - Effectiveness of antiangiogenic drugs (ADs) in glioblastoma (GBM) patients (PTS): A metanalysis of randomized clinical trials (RCTs)

Giuseppe Lombardi, Padua, Italy

16:30 Invited discussant abstracts 326PD, 327PD and 328PD

Andreas Hottinger, Lausanne, Switzerland

16:50 Questions to discussant

329PD - Survival of patients with synchronous and metachronous breast cancer and meningioma

Catarina Ribeiro, Lisbon, Portugal

330PD - Temporal muscle thickness (TMT) is an independent prognostic parameter in patients with newly diagnosed brain metastases (BM) of breast cancer (BC)

Anna Sophie Berghoff, Vienna, Austria

331PD - Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)

Christian Grommes, New York, NY, USA

17:00 Invited discussant abstracts 329PD, 330PD and 331PD

Deborah Blumenthal, Tel Aviv, Israel

17:20 Questions to discussant

Sunday, 9 October 2016 - 08:00/09:00 – page 112

Room Rome

CONTROVERSY SESSION

Rectal cancer: What is the optimal time for surgery?

Chair: Karen-Lise Spindler, Aarhus, Denmark

08:00 Introduction and first vote

Karen-Lise Spindler, Aarhus, Denmark

08:10 To wait seems better

Ian Chau, London, UK

08:30 The sooner the better

Jérémie Lefevre, Paris, France

08:50 Second vote and conclusions

Karen-Lise Spindler, Aarhus, Denmark

Sunday, 9 October 2016 - 09:15/10:45 – page 114

Room Zagreb

SPECIAL SESSION

Adaptive licensing (MAPPs)

Chairs: Paolo G. Casali, Milan, Italy and Bettina Ryll, Uppsala, Sweden

09:15 Regulatory perspectives in MAPPs and the EMA pilot

Francesco Pignatti, London, UK

09:30 MAPPS from the HTA perspective

Sarah Garner, London, UK

09:45 The industry perspective

Thomas Allvin, Brussels, Belgium

10:00 The clinician's perspective: Learning from the rare disease community

Paolo G. Casali, Milan, Italy

10:15 The patient perspective: Patient - centric drug development

Bettina Ryll, Uppsala, Sweden

10:30 Discussion: Challenges

NSCLC, metastatic 1

Chair: Egbert Smit, Amsterdam, Netherlands

Co-Chair: Solange Peters, Lausanne, Switzerland

11:00 **LBA42_PR** - Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study
Giorgio Scagliotti, Orbassano, Italy

11:15 **12080** - Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)
Enriqueta Felip, Barcelona, Spain

11:30 Invited discussant abstracts LBA42_PR and 12080
Egbert Smit, Amsterdam, Netherlands

11:45 **LBA43** - Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC): Overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)
Luis Paz-Ares, Madrid, Spain

12:00 **12010** - Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis
Tony S.K. Mok, Hong Kong, China

12:15 Invited discussant abstracts LBA43 and 12010
Pasi Jänne, Boston, MA, USA

Gastrointestinal tumours, colorectal 1

Chair: Richard Adams, Cardiff, UK

Co-Chair: Volker Heinemann, Munich, Germany

14:45 **4520** - Results of a prospective randomized control 6 vs 12 trial: Is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy?

Jemma Bhoday, London, UK

14:57 **4530** - Scheduled use of CEA and CT follow-up to detect recurrence of colorectal cancer: 6-12 year results from the FACS randomised controlled trial

Sian Pugh, Southampton, UK

15:09 Invited discussant abstracts 4520 and 4530

Florence Huguet, Paris, France

15:24 **LBA20_PR** - Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUMECOLON 1 study

Eric Van Cutsem, Leuven, Belgium

15:36 **4540** - A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): The CCTG/AGITG CO.23 trial

Derek Jonker, Ottawa, ON, Canada

15:48 **4550** - Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E-mutated (BRAFM) metastatic colorectal cancer (mCRC)

Ryan Corcoran, Boston, MA, USA

16:00 Invited discussant abstracts LBA20_PR, 4540 and 4550

Volker Heinemann, Munich, Germany

16:25 **LBA4** - Patient-Reported Outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (nivo) or Investigator's Choice (IC): CheckMate 141

Kevin Harrington, London, UK

16:40 Invited discussant LBA4

Anthony Chan, Hong Kong, China

16:50 **LBA46_PR** Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G

Corey Langer, Philadelphia, PA, USA

17:05 **LBA8_PR** - KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) $\geq 50\%$

Martin Reck, Grosshansdorf, Germany

17:20 Invited discussant LBA46_PR and LBA8_PR

Jean-Charles Soria, Villejuif, France

17:35 **LBA7_PR** - CheckMate 026: A Phase 3 trial of nivolumab vs Investigator's Choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage IV/recurrent programmed death ligand 1 (PD-L1) – positive NSCLC

Mark Socinski, Pittsburgh, PA, USA

17:50 **LBA44_PR** - Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC

Fabrice Barlesi, Marseille, France

18:05 Invited discussant LBA7_PR and LBA44_PR

Naiyer Rizvi, New York, NY, USA

Sunday, 9 October 2016 - 16:30/18:00 –page 132

Room Oslo

SPECIAL SYMPOSIUM

Precision medicine in NETs: Myth or reality?

Chair: Rocio Garcia-Carbonero, Madrid, Spain

Co-Chair: Kjell Oeberg, Uppsala, Sweden

16:30 Introduction

Rocio Garcia-Carbonero, Madrid, Spain

16:35 Molecular tumour profiling and upcoming biomarkers: Will they help to deliver personalised medicine?

Timothy Meyer, London, UK

16:50 Minimally invasive surgery: Does it improve precision?

Massimo Falconi, Milan, Italy

17:05 Nuclear medicine: What do novel isotopes add to the treatment of NETs?

Andreas Kjaer, Copenhagen, Denmark

17:20 Targeted drugs: Where are we now?

Marianne Pavel, Berlin, Germany

17:35 Targeted drugs: Where are we heading to?

Eric Raymond, Lausanne, Switzerland

17:50 Conclusions and clinical perspectives

Kjell Oeberg, Uppsala, Sweden

Sunday, 9 October 2016 - 16:30/18:00 –page 134

Room Helsinki

EDUCATIONAL SESSION

Bad luck or bad knowledge? Evidence-based cancer prevention approaches

Chair: Jack Cuzick, London, UK

Co-Chair: Silvia Franceschi, Lyon, France

16:30 Where to give prevention advice

Gauden Galea, Copenhagen, Denmark

17:00 Proven interventions

Silvia Franceschi, Lyon, France

17:30 Unproven interventions

Gareth Evans, London, UK

Sunday, 9 October 2016 - 18:00/19:30 – page 138

Room Zagreb

PATIENT ADVOCACY TRACK

Why do side-effects matter and how to generate data on them

Chair: Ananda Plate, Brussels, Belgium

Co-Chair: Gilliosa Spurrier-Bernard, Clermont-Ferrand, France

18:00 Why the reporting of side-effects is so important

Dimitrios Athanasiou, Athens, Greece

18:15 How differently clinicians, patients and carers perceive side effects

Ananda Plate, Brussels, Belgium

18:30 New drugs that are safe: Pharmacovigilance in oncology

Florence van Hunsel, Hertogenbosch, Netherlands

18:45 Innovative ways to record treatment side effects in clinical trials

To be announced

19:00 Patient networks driving adverse event reporting: The UMC/ MPNE project

Rebecca Chandler, Uppsala, Sweden

19:15 Discussion: What can we as patient advocates do to:

- Increase the safety of our therapies?
- Ensure that side effects are evaluated according to the true impact for patients?

Monday, 10 October 2016 - 09:15/10:15 – page 178 – revised session

Room Vienna

PROFFERED PAPER SESSION

NSCLC, metastatic 2

Chair: Tony S.K. Mok, Hong Kong, China

Co-Chair: Fiona Blackhall, Manchester, UK

09:15 **LBA45** - Top-line results from SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Baviximab Plus Docetaxel in Patients with Previously Treated Stage IIIb/IV Non-Squamous Non Small Cell Lung Cancer

David Spigel, Nashville, TN, USA

09:30 **LBA47_PR** - Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial

Pasi Jänne, Boston, MA, USA

09:45 **12020** - Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Charlotte Leduc, Strasbourg, France

10:00 Invited discussant abstracts LBA45, LBA47_PR and 12020

Tony S.K. Mok, Hong Kong, China

Monday, 10 October 2016 - 09:15/10:45 – page 179

Room Brussels

JOINT SYMPOSIUM: ESMO-DSKO

Perspectives in the registration and use of Big Data and individual molecular profiles

Chairs: Fortunato Ciardiello, Naples, Italy and Ulrik Lassen, Copenhagen, Denmark

09:15 Introduction

Fortunato Ciardiello, Naples, Italy

09:20 The value of a large clinical database in testicular cancer

Gedske Daugaard, Copenhagen, Denmark

09:40 Big Data/cancer epidemiology

Søren Brunak, Copenhagen, Denmark

10:00 International collaboration with molecular profiling (WIN)

Vladimir Lazar, Villejuif, France

10:20 **Understanding how immunotherapy works by dissecting the tumour specific T cell response**

Sine Reker Hadrup, Copenhagen, Denmark (TBC)

10:40 Conclusions and clinical perspectives

Ulrik Lassen, Copenhagen, Denmark

Monday, 10 October 2016 - 09:30/10:30 – page 180

Room Helsinki

MULTIDISCIPLINARY PATIENT CASES

Targeting the genes is not enough: The patients and tumour behaviour also matter

Chair: Alice Shaw, Boston, MA, USA

09:30 One mutation, many cancers

David Huntsman, Vancouver, BC, Canada

09:40 Resistance mutations and cell context specific adaptive responses

Alice Shaw, Boston, MA, USA

09:50 Considering clonal evolution in breast cancer management

Carlos Caldas, Cambridge, UK

10:00 Discussion

Endocrine and neuroendocrine tumours

Co-Chairs: Rocio Garcia Carbonero, Madrid, Spain; Eric Baudin, Villejuif, France and Xavier Matias-Guiu, Lleida, Spain

420PD - NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate:

Efficacy, safety, QoL results and subgroup analysis

Jonathan Strosberg, Tampa, FL, USA

421PD - Impact of prior therapies on everolimus treatment in the subgroup of patients with advanced lung neuroendocrine tumors (NET) in the RADIANT-4 trial

Roberto Buzzoni, Milan, Italy

422PD - Integrated placebo-controlled safety analysis from clinical studies of telotristat etiprate for the treatment of carcinoid syndrome

Matthew Kulke, Boston, MA, USA

423PD - Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)

Martin Gutierrez, Hackensack, NJ, USA

11:00 Invited discussant abstracts 420PD, 421PD, 422PD and 423PD

Rocio Garcia Carbonero, Madrid, Spain

11:10 Questions to discussant

424PD - Prevalence of gastroenteropancreatic and lung neuroendocrine tumours in the European Union

Anthony Berthon, Boulogne-Billancourt, France

425PD - Multicentre evaluation of the role of Gallium DOTA-PET (GaPET) imaging in well differentiated bronchial carcinoids (BC): Impact on patients' (pts) management

Angela Lamarca, Manchester, UK

426PD - A population based analysis of outcome of chemotherapy for metastatic pulmonary large cell neuroendocrine carcinomas: Does the regimen matter?

Jules Derks, Maastricht, Netherlands

11:20 Invited discussant abstracts 424PD, 425PD and 426PD

Eric Baudin, Villejuif, France

11:30 Questions to discussant

427PD - Pediatric, adolescent and young adult (PAYA) thyroid carcinoma harbors frequent and diverse targetable genomic alterations including kinase fusions

Siraj Ali, Cambridge, MA, USA

428PD - Damaging germline variants in TSC2 are frequently found among nonsyndromic patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NETs)

Rudinei Linck, Sao Paulo, Brasil

11:40 Invited discussant abstracts 427PD and 428PD

Xavier Matias-Guiu, Lleida, Spain

11:50 Questions to discussant

Monday, 10 October 2016 - 11:00/12:30 – page 185

Room Helsinki

SPECIAL SYMPOSIUM

Streamlining the equitable delivery of anticancer drugs: Sharing common grounds for a pan-European vision of value

Chair: Rosa Giuliani, Rome, Italy

Co-Chair: Alexandru Eniu, Cluj-Napoca, Romania

11:00 Introduction

Alexandru Eniu, Cluj-Napoca, Romania

11:05 Equitable and affordable cancer care: Is Europe a union for real?

Richard Sullivan, London, UK

11:20 How the European Commission's HTA initiative and the HTA network can promote consistent assessment of cancer care treatments in the EU

Andrzej Rys, Brussels, Belgium

11:35 The EMA's initiatives to speed up access to valuable cancer drugs: Adaptive pathways and flexible approaches

Francesco Pignatti, London, UK

11:50 Industry's initiatives to reduce inequities and increase access to valuable cancer care: Myth or reality?

Thomas Allvin, Brussels, Belgium

12:05 ESMO's initiatives to reduce disparities in cancer care: Promoting access to valuable drugs focusing on the magnitude of benefit

Elisabeth de Vries, Groningen, Netherlands

12:20 Conclusions and clinical perspectives

Rosa Giuliani, Rome, Italy

Monday, 10 October 2016 - 11:15/12:50

Room Copenhagen

SPECIAL SESSION

Right or Left metastatic colon cancer: Will the side change your treatment?

Chair: Fortunato Ciardiello, Naples, Italy

Co-Chair: Josep Tabernero, Barcelona, Spain

11:15 Introduction

Fortunato Ciardiello, Naples, Italy

11:20 Sidedness in colon cancer

Heinz Josef Lenz, Los Angeles, CA, USA

11:35 Outcome according to Left vs. Right side in the Panitumumab studies

Marc Peeters, Edegem, Belgium

11:50 Outcome according to Left vs. Right side in the FOLFIRI Cetuximab FIRE 3 study

Volker Heinemann, Munich, Germany

12:00 Outcome according to Left vs. Right side in the FOLFIRI Cetuximab CRYSTAL study

Eric Van Cutsem, Leuven, Belgium

12:10 Outcome in the CALGB 80405

Heinz Josef Lenz, Los Angeles, CA, USA

12:25 Pro Discussion

Dirk Arnold, Lisbon, Portugal

12:35 Contra Discussion

Andrés Cervantes, Valencia, Spain

12:45 Conclusions

Josep Tabernero, Barcelona, Spain

Monday, 10 October 2016 - 16:30/18:10 – page 195 – revised session

Room Copenhagen

PRESIDENTIAL SYMPOSIUM

Presidential Symposium 3

Chair: Fortunato Ciardiello, Naples, Italy

Co-Chair: Andrés Cervantes, Valencia, Spain

16:30 **LBA6_PR** - Full-dose neoadjuvant anthracycline + ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial

Alessandro Gronchi, Milan, Italy

16:45 Invited discussant LBA6_PR

Axel Le Cesne, Villejuif, France

16:55 **LBA9_PR** - Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC)

Karim Fizazi, Villejuif, France

17:10 Invited discussant LBA9_PR

Ronald de Wit, Rotterdam, Netherlands

17:20 **LBA30_PR** - CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial

Toni Choueiri, Boston, MA, USA

17:35 Invited discussant LBA30_PR

Bernard Escudier, Villejuif, France

17:45 **LBA11_PR** - Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)

Alain Ravaud, Bordeaux, France

18:00 Invited discussant LBA11_PR

Axel Bex, Amsterdam, Netherlands